Cancer Research | Penn Today

Carl June: 2024 will be seen as a breakthrough year for brain cancer

Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.

Penn plans to build a proton center for cancer treatment at Presbyterian Medical Center

Penn Medicine will build its fourth proton beam center for cancer treatment at Penn Presbyterian Medical Center in University City.

A newly identified immune checkpoint protein may lead to future cancer therapies

Penn Medicine researchers have found that knocking out a T cell’s CD5 gene greatly enhances the cell’s anticancer activity in a variety of preclinical cancer models.

Double mastectomies do not improve breast cancer survival likelihood for most women, study finds

Angela DeMichele of the Perelman School of Medicine says that chemotherapy and hormonal therapies are important for combating breast cancer because they’re designed to kill spreading cells.

Breast cancer survival not boosted by double mastectomy, study says

Angela DeMichele of the Perelman School of Medicine comments on a study which found that breast cancer survival is not boosted by a double mastectomy.

How did Shannen Doherty die? What to know about ‘90210’ star’s cause of death

According to Penn Medicine, there is no known cure for metastatic breast cancer.

3D illustration showing cross-section of the lipid nanoparticle carrying mRNA of the virus entering a human cell.

Penn pioneers a ‘one-pot platform’ to promptly produce mRNA delivery particles

New lipid platform enables rapid synthesis of molecules that can shuttle therapeutics for a range of diseases with a high degree of organ specificity.

Two nurses guiding a prone patient into a proton imaging machine.

The power of protons

Penn Medicine has treated more than 10,000 cancer patients at three proton therapy centers across the region, including the largest and busiest center in the world—while also leading the way in research to expand the healing potential of these positive particles.

Internal view of lungs with a cancerous growth.

Slowing inflammation may boost immunotherapy’s effectiveness against advanced lung cancer

Patients with stage 4 lung cancer show high response rates after an anti-inflammatory drug is added temporarily to immune checkpoint inhibitor therapy.

New immunotherapy combination could ‘change the landscape’ of cancer treatment

A study by Andy Minn and postdoc Divij Mathew of the Perelman School of Medicine and colleagues found that a combination checkpoint inhibitor therapy benefited patients with lung cancer.

Filters